Drug
In10018 IN Combination With Pld
In10018 IN Combination With Pld: highest development phase Phase 1/2, developed by InxMed (Shanghai) Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- InxMed (Shanghai) Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| IN10018 in combination with PLD NCT05551507 | Phase 1/2 | Platinum-resistant Ovarian Cancer |
Latest
No recent events.
Follow In10018 IN Combination With Pld on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.